Menopause Treatment Market: Drivers, Restraints, Opportunities, and Threats (2020-2027)

 Market Synopsis

Market Research Future (MRFR) studied the Global Menopause Treatment Market 2020 for the study period 2020 to 2027. As per MRGR analysis, the menopause treatment market can rise at 6.18% CAGR in the review period. By 2027, the menopause treatment value can reach USD 15,456.3 Million.

The increases in cases of menopause complication is creating the need for menopause treatment, which can impact the expansion of the market across the analysis period. The increase in government initiatives to promote health of women and menstrual hygiene contribute significantly to the awareness about menopause treatments available. This can support the expansion of the market across the analysis period. In addition, the launches for effective products for menopause treatments by multiple private and public suppliers can cause the global market to flourish, as the competition among these players intensify during the assessment period. On the contrary, unless side-effects of menopause hormonal treatments are resolved, it can hamper the rise of the menopause treatment market in the approaching years.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4579 

Market Segmentation

The segment assessment of the Global Menopause Treatment Market is done by Treatment and Distribution Channels.

The treatment based segment of the menopause treatment market are non-hormonal treatment and hormonal treatment. The hormonal treatment segments are progesterone, estrogen, and combination. Hormonal treatments were largely prescribed over the years until, the effective non-hormonal treatments were introduced. The increase in the ability to non-hormonal treatment to alleviate menopausal symptoms, especially hot flashes and vaginal dryness can support the expansion of the menopause treatment market in the analysis period. The non-hormonal treatments are anti-depressants and others

The distribution channel based segments of the menopause treatment market are retail pharmacies, hospital pharmacies, and online stores. The hospital pharmacies segment can earn high revenue for the market across the analysis period. The segment can thrive at 6.59% CAGR in the analysis period. The increase in older women populace and surge in awareness and uptake about menopausal treatments can support the market expansion.

Regional Analysis

MRFR regional assessment of the menopause treatment market states that Americas market can secure the largest share of the worldwide market in the study period. The existence of renowned players in the US, along with rise in the uptake of hormonal therapy can prompt the expansion of the menopause treatment market in the review period. The easy of product clearances by different regulatory authorities can improve the expansion of the regional menopause treatment market in the review period.

In Europe, the menopause treatment market surge can be attribute to the increase in the adoption of menopause treatment solutions by the rising cases of urogenital complications and vasomotor symptoms observed in women. The presence of effective healthcare infrastructure base can also report the Europe market.

In Asia Pacific, the spreading awareness about women’s health can improve the regional market rise. In addition, the entry of new players and new tie-ups among regional distributors and vendors can impact the expansion of the market through the study period. 

Key Players 

Novo Nordisk A/S (Denmark), Allergan (Ireland), Pfizer Inc. (US), Novartis AG (Switzerland), Eli Lily and Company (US), Teva Pharmaceuticals (Israel), Emcure Pharmaceuticals Ltd (India), Cipla Inc. (India), Abbott Laboratories (US), and Merck & Co., Inc. (US) among others are some reputed companies that are functioning in the Menopause Treatment Market as enlisted by MRFR.

Industry News

August 2020

A study published by University Of Colorado School Of Medicine reveals that non-hormonal therapy can treat hot flashes and other type of menopause issues. The rise in application of modern non-hormonal solutions can support the market rise.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/menopause-treatment-market-4579 

Interventional Cardiology Market to Witness Widespread Expansion During 2020-2027

 According to MRFR analysis, the Global Interventional Cardiology Market is expected to register a CAGR of 7.25% from 2019 to 2025 and held a value of USD 15,130.75 Million in 2018.

The interventional cardiology market is driven by several factors, such as technological advancements in interventional cardiac devices, rising prevalence of cardiac diseases, increasing preference for minimally invasive procedures, and increasing geriatric population. For instance, approximate 500,000 patients around the world undergo percutaneous coronary intervention each year for stable angina, and the procedure is considered to provide substantial relief from pain symptoms to patients.

Many market players are dominating the global interventional cardiology market. The prominent players are involved in strategic agreements, product launches, and joint ventures to brace their market positions. For instance, in May 2018, Terumo Europe NV announced the launch of Ultimate Tensei drug-eluting stent in Europe.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8735 

Segmental Analysis

The segmental overview of the interventional cardiology market is carried out on the basis of type, end user, and regions. The type segment of the interventional cardiology market consists of plaque modification devices, coronary guidewires, accessories, stents which further includes bare metal stents, drug-eluting stents, and bioresorbable vascular scaffolds, percutaneous transluminal coronary angioplasty (PTCA) catheters such as balloon catheters and guiding catheters. The region segment of the interventional cardiology market consists of Europe, the Americas, Asia-Pacific, and the Middle East & Africa. The end-user segment of the interventional cardiology market consists of cardiac catheterization laboratories, hospitals, and ambulatory surgical centers.

Regional Overview

The regional assessment of the interventional cardiology market consists of Europe, the Americas, Asia-Pacific, and the Middle East & Africa. The Americas interventional cardiology market was the major regional market in 2018 due to the augmented cases of coronary diseases in this region. Percutaneous coronary intervention is one of the two most common practices executed on patients with coronary artery disease in the U.S. The European region's interventional cardiology market holds the next principal share due to an augmented number of hospitalizations for practices such as cerebral angioplasty and carotid artery angioplasty. The Asia Pacific region's interventional cardiology market is foreseen to be the fastest mounting region in the global market. The producers' advantageous marketing initiatives are performing a considerable role in growing the target audience and consequently growing the Interventional cardiology market size in this region. Similarly, the upsurge in the setups of research and development hubs and the increase in the number of collaborations are driving the growth of the interventional cardiology market in this region.

Competitive Analysis

The development of novel production processes is likely to enhance market strength further. The stabilization of demand and supply forces is estimated to open up opportunities for expansion in the forecast period. The market is estimated to derive momentum from improvement in operating systems within the market. As the market players understand the advantages of a lean operation framework, the market is estimated to transform considerably. The role of the government bodies in almost every country is estimated to be valuable to restore normalcy and create a growth outlook. The forging of novel international trade relations is estimated to bolster the market's capabilities in the upcoming period. The fast-paced adoption of online services and selling platforms is estimated to reinforce market progress in the upcoming years. The consolidation of market competition is predicted to usher in a new development phase in the impending period. The earmarked budget for innovation is set to rise with companies realizing the impact of having a progressive product assortment.

The distinguished companies in the interventional cardiology market are Abbott (U.S.), Cook Medical (U.S.), Life Vascular Devices Biotech S.L. (Spain), ACIST Medical Systems, Inc. (the U.S.), B.D. (U.S.), Boston Scientific Corporation (U.S.), Biotronik SE & Co. K.G. (Germany), Cardinal Health (U.S.), Medtronic (Ireland), Edwards Lifesciences Corporation (U.S.), G.E. Healthcare (U.S.), Koninklijke Philips N.V. (Netherlands), ABIOMED (U.S.), Biosense Webster, Inc (U.S.), Merit Medical Systems, Inc (U.S.), Terumo Corporation (Japan), B. Braun Melsungen AG (Germany), and W. L. Gore & Associates, Inc. (U.S.).

Industry Updates:

May 2021 A partnership of the University of South Florida's Health Interventional Cardiology Group and Tampa General Hospital (TGH) have accepted a novel intravascular imaging technology and completed the first such technique in the world. The novel intravascular technology, named High-Frequency Optical Coherence Tomography (HF-OCT), was lately performed on a patient with serious coronary artery disease, which was the primary such fruitfully treated in the world. Tampa General has been an initial adopter of intravascular imaging for coronary intervention and persists in seeking the latest and finest technology. The team has combined intravascular ultrasound (IVUS) and intravascular optical coherence tomography to see inside the blood vessels.

May 2021 Abbott recently announced its novel interventional imaging platform driven by Ultreon 1.0 Software, which acquired a European C.E. mark. This first-of-its-kind imaging software combines optical coherence tomography (OCT) intravascular imaging with the control of artificial intelligence (A.I.) for improved visualization. The novel Ultreon Software can automatically notice the seriousness of calcium-based blockages and gauge vessel diameter to improve the exactness of physicians' decision-making throughout coronary stenting procedures.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/interventional-cardiology-market-8735 

Proteomics Market Growth, Trends and Value Chain 2020-2027

 Understanding the benefits of customized medication is estimated to play a major role in the development of the proteomics market. Market's report is efficiently analyzed as per MRFR, which provides outlooks for the global markets. By 2023, the market is estimated to observe a 14.1% CAGR.

The development of the production potential of the contenders in the global market is estimated to hasten the growth of the proteomics market share in the impending period. The improvement in distribution channels of this specific kind of medication is assessed to further advocate its development in the course of the forecast period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6930 

Segmental Analysis

The segmental assessment of the proteomics market is carried out on the basis of equipment, services, application, and region. The equipment segment of the proteomics market consists of mass spectroscopy, protein microarray, chromatography, x-ray crystallography, and protein fractionation. The region segment of the proteomics market consists of Europe, Asia Pacific, the Americas, and the Middle East & Africa. The service segment of the proteomics market consists of data analysis & services and laboratory services. The application segment of the proteomics market consists of clinical diagnosis and drug discovery.

Regional Overview

The regional examination of the proteomics market consists of Europe, Asia Pacific, the Americas, and the Middle East & Africa. The Americas region's proteomics market is expected to govern the global market due to rising backing from the government, cost-effectiveness, intensifying knowledge regarding proteomics applications, and collective call for modified medicines. The European regional proteomics market is anticipated to control the next principal place in the global market. The proteomics market growth in the European region is ascribed to intensifying cancer research activities and government support. The Asia Pacific region's proteomics market is anticipated to be the quickest developing region due to the growing call for modified medicine due to increasing cancer and other such illnesses and the incidence of many producers of modified medication in the region.

Competitive Analysis

The role of government bodies is estimated to be essential to the development of the market. The presence of online channels is predicted to enhance the market's advancement in the upcoming years. The role of innovation is estimated to become even more critical for progress as the market grows. The trends in the market are estimated to bolster the progress in the worldwide market. The foray of digitization-based methods into operation management and forecasting is predicted to transform the global market in the forecast duration. The tendency to invest and expand capacities is estimated to create a good scope for the market in the upcoming years. The market is predicted to be driven by the effects of the COVID-19 pandemic by ensuring that businesses can counteract situations like these in the future. The overall support to rebuilding economic growth momentum is estimated to be increased than the past few years. The formation of solid trade relations among several regions is forecasted to have a beneficial effect on growth. The upgrades in delivery strategies are anticipated to boost the market progress further shortly.

The promising companies in the proteomics market are Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., WATERS, Danaher, Merck KGaA, GENERAL ELECTRIC COMPANY, Thermo Fisher Scientific Inc. Inc., Genzyme Corporation, Siemens Ltd., Biognosys AG, Bruker, Luminex Corporation, PerkinElmer Inc., and Caprion Biosciences Inc.

Industry Updates:

May 2021 Canopy Biosciences, a Bruker Company, revealed the fruitful development of a novel assay for exploratory immune response to COVID-19. The assay expends high-plex spatial proteomics and is accomplished on Canopy's ZellScannerONE precise spatial phenotyping gadget. ZellScannerONE allows multiplexed spatial quantification of protein biomarkers in tissue specimens, as well as in suspended cells. The COVID-19 Immune Response Assay will be accessible firstly as a service, executed by Canopy on researcher-supplied specimens, and a reagent kit will be offered at a later date.

May 2021 Proteomics International Laboratories has selected an analytical services agreement in pharmacokinetic testing worth USD 243,000 with Avance Clinical, one of Australia's major clinical trial contract research bodies. Proteomics has revealed the contract includes carrying out a pharmacokinetic examination of a novel medication for lysosomal storage disorder. Proteomics also declares the contract is its greatest analytical services contract to date and marks the coming back of its analytical services activity to pre-pandemic heights of development.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/proteomics-market-6930 

Bowel Management Systems Market to Witness Widespread Expansion During 2020-2027

Market Research Future (MRFR), in their recently launched report, has asserted that the global bowel management systems market is expected to showcase a steady CAGR of 4.1% over the forecast period. The global bowel management systems market is estimated to reach a market valuation of USD 2.188 billion between the forecast period of 2017-2023. Various factors are attributing to the accelerated growth noted in the global bowel management systems market.

A rapid change in lifestyles of the general public has led to a surge in the intestinal issues such as constipation and fecal incontinence. Advancements in healthcare technology, along with various technological developments in medical devices, has pushed sizeable growth in the bowel management systems market. Further, the rise of the geriatric population, across the globe, has propelled the surging bowel management systems market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6649 

Additionally, the dietary imbalance caused due to the consumption of unhealthy food is also causative of fast-paced growth noted in the global bowel management systems market. However, on the other hand, concerns regarding the discomfort associated with the use of bowel management devices are likely to pose as a hindrance in the ascension of the global bowel management systems market. Also, an inclination towards the adoption of non-invasive and minimally invasive treatments is anticipated to restrain the bowel management systems market from upscaling during the forecast period.

Market Segmentation

The global bowel management systems market is studied for various segments based on products, patient types, end-user, and region. Based on product, the global bowel management systems market is segmented into irrigation systems, nerve modulation devices, and colostomy bags. The colostomy bags segment is expected to hold the biggest share of the global bowel management systems market. On the other hand, the nerve modulation devices (NMD) segment is expected to ascend at the fastest rate during the forecast period.

Based on patient types, the global bowel management systems market is segmented into pediatric patients and adult patients. The adult patients segment is estimated to hold the major share of the global bowel management systems market over the forecast period.

Based on end-users, the global bowel management systems market is studied for the segments of hospitals and ambulatory surgery centers, and home care. The home care segment spearheads the global bowel management systems market.

Detailed Regional Analysis

The bowel management systems market is analyzed for the regional segments of the Americas, Europe, Asia Pacific, and the Middle East & Africa. The Americas are anticipated to dominate the global bowel management systems market over the forecast period. This can be due to the rapid adoption of technologically advanced healthcare solutions and a high prevalence of intestinal disorders causative of rising adoption of an unhealthy lifestyle and eating habits. Increasing prevalence of the geriatric population and ascending healthcare expenditure are other factors contributing to the heavy ascension of the regional bowel management systems market.

Mounting research activities for the development of comfortable bowel management systems has pushed the bowel management systems market prevalent in Europe. Moreover, faster adoption of advanced technology is encouraging growth in Europe’s bowel management systems market.

Asia Pacific is projected to exhibit the fastest growth rate in the bowel management systems market over the assessment period. This can be owed to the fast-paced development of the healthcare sector in the region. Further, rising awareness of the availability of effective bowel management treatments has contributed to the heavy ascension noted in the regional market over the forecast period. An upscaling in the geriatric population residing in the region has led to a rising need for bowel management systems.  

The Middle East & Africa is expected to showcase slow growth for bowel management systems market over the assessment period. This can be accredited to the lack of awareness and the presence of poor healthcare facilities in the region.

Key Players

The global bowel management systems market boasts the presence of many prominent market players including Medtronic (Ireland), Coloplast (Denmark), 3M (the U.S.), Aquaflush Medical Limited (the U.K.),  Hollister (the U.S.), B. Braun (Germany), Consure Medical (India), C.R. Bard (the U.S.), Cogentix Medical (the U.S.), ConvaTec (the U.K.), Axonics Modulation Technologies (the U.S.), MBH-International A/S (Denmark), Welland Medical limited (the U.K.), Mederi Therapeutics Inc. (the U.S.), and Wellspect HealthCare (Sweden).

Industry Update

August 2019: Axonics Modulation Technologies recently announced the completion of their one-year follow-ups and clinical results from ARTISAN SNM pivotal study conducted under the US FDA. Axonics has developed and is providing Sacral Neuromodulation (SNM) device, on a commercial scale, for the treatment of urinary and bowel dysfunction.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/bowel-management-systems-market-6649 

Artificial Neural Network Market – Insights on Upcoming Trends 2027

 Market Dynamics 

An artificial neural network is a form of artificial intelligence which is based on the structure and functions of human neural networks. The artificial neural network software can be used for medical research, drug development, clinical diagnosis of various diseases, and interpretation of clinical imaging techniques, among others.

Key factors driving the growth of the market are the emergence of artificial intelligence, increasing healthcare expenditures by the government in developed regions, and increasing adoption of the artificial neural network in the healthcare sector. Moreover, the increasing prevalence of several chronic diseases globally is likely to contribute to the growth of the artificial neural network. In January 2017, a scientist demonstrated that the IBM Watson for oncology would be a reliable Artificial Intelligence (AI) system for assisting the diagnosis of cancer.

However, slow digitization across emerging regions and reluctance among healthcare professionals to adopt artificial intelligence-based technologies are some factors that can hinder the growth of the market during the forecast period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6287 

Regional Analysis

The market in the Americas is expected to dominate the global artificial neural network market during the forecast period owing to the well-established healthcare sector, the presence of a large number of companies such as Microsoft Corporation, Intel Corporation, and Google Inc. engaged in the development of neural network technologies, and growing adoption of artificial intelligence in the healthcare sector. The European market is expected to be the second-largest market due to the increasing preference for artificial intelligence among healthcare providers, growing healthcare expenditure, and rising prevalence of chronic diseases. Moreover, the market in Asia-Pacific is anticipated to be the fastest-growing during the forecast period owing to technological development and favorable government initiatives for healthcare facilities. The market in the Middle East & Africa is likely to account for the least market share of the global artificial neural network market. The market growth in this region can be attributed to growing technological implementations and increasing healthcare expenditures.

Segmentation

The global artificial neural network market has been segmented into type, component, and application.

The market, on the basis of type, has been segmented into feedback artificial neural network, feedforward artificial neural network, and others.

The market, by component, has been segmented into software, services, and platform.

The global artificial neural network market, by application, has been segmented into clinical diagnosis and prognostics, image analysis and interpretation, bioelectric signal analysis and interpretation, drug development, and others.

Global Artificial Neural Network Key Players

Some of the prominent players in the global artificial neural network market are Starmind International AG, Neural Technologies Limited, SwiftKey,  Afiniti, Ward Systems Group, Inc., SAP SE, NeuroDimension, Inc., Alyuda Research, LLC., Google Inc., Neuralware, Qualcomm Technologies, Inc., Intel Corporation, Microsoft Corporation, IBM Corporation, and Oracle Corporation.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/artificial-neural-network-market-6287 

Artificial Eye Market Dynamics, Segments and Supply Demand 2020-2027

 Market Dynamics 

The growing number of people who are blind or partially blind is driving the global artificial eye market. The global artificial eye market is being driven by an increase in the number of people who are blind or partially blind, as well as an aging population. The market is also growing due to the rising prevalence of diseases that affect vision, technological advancements, and the prevalence of diseases such as diabetes. The market's development has been slowed by the high cost of care and the availability of low-cost alternatives. Over the forecast period, the artificial eye market will be driven by rising cases of ophthalmic defects and injuries. The market for artificial eyes is expected to rise as technology advances.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/985 

Furthermore, there are a variety of insurance plans that make surgery accessible to a wide range of people. To ease the financial strain, the United States and several other countries have compensation coverage for medical care through different insurance schemes. Government campaigns to help patients all over the world facilitate reimbursement programs. As a result, demand for artificial eyes will rise over the forecast period. Furthermore, rising medical tourism for low-cost artificial eye implantation procedures and technological advancements in artificial eye advancement are major factors driving market growth. However, the high cost of artificial eyes, as well as the high cost of implantation procedures related to artificial eyes, could stifle industry development. 

Segmental Analysis 

Global artificial eye market is segmented on the basis of type, Non-integrated implants, Integrated implants. Integrated implants are further segmented into hydroxyapatite, porous polyethylene, bioceramic, conical orbital implant and other. On the basis of technology, they are segmented into electronic and mechanical and on the basis of end user, the market is segmented into hospitals, ophthalmology clinics and others. 

Regional Analysis 

On regional basis, global artificial eye market is segmented into four major regions namely Americas, Europe, Asia Pacific and Middle East and Africa.  

Because of its large geriatric population and growing number of people suffering from vision impairment, America leads the global artificial eye industry. According to the American Academy of Ophthalmology, more than a quarter of the population in the United States has a minor or major visual complication, and this figure is steadily increasing due to the growing diabetic population. Because of increased product innovation, increased presence of leading players, increased favorable reimbursement policies, and high acceptance of artificial eye surgeries in this area, North America dominates the artificial eye market. Due to the presence of qualified professionals, highly developed healthcare infrastructure, technological advances, and the presence of large market players in the region, the United States dominates the global artificial eye market. In addition, the country's large healthcare expenditures would drive business growth.

Because of increased construction activities, increased healthcare spending per person, and government support in this area, Europe has the second largest artificial eye market in terms of growth. The European artificial eye market will continue to be driven by rising demand for custom-made ocular prostheses and the the prevalence of ophthalmic diseases.

The artificial eye market in Asia Pacific is rising at the fastest pace. Because of their well-developed healthcare sectors and high health-care spending, Japan and Australia are the leading contributors to the industry. Because of technological advances, the disposable incomes, and the innovations in the healthcare system, Japan is expected to see substantial growth in the artificial eye market during the study era. Artificial eye demand will be boosted by the factors listed above.

Owing to a lack of medical services and weak economic and political conditions, the Middle East and Africa has the smallest market share. The artificial eye market in the Middle East and Africa is dominated by Saudi Arabia, the United Arab Emirates, and Kuwait.

Competitive Analysis 

Advanced Artificial Eye (US), The National Artificial Eye Services (NHS) (UK), Marie Allen Ocularist Ltd (Canada), COS-MEDIC PTY LTD (Australia), Retina Implant AG (Germany), Second Sight (US), Pixium Vision (France), Ericksons Custom Made Artificial Eye (Canada), International Prosthetic Eye Center (India) are among the major market players. The global artificial eye market is fragmented, with many small players competing for market share with a few large players. Partnerships, mergers, acquisitions, and the introduction of new products are some of the major strategic steps taken by market leaders to broaden their company product range.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/artificial-eye-market-985 

Global Chinese Fibromyalgia Market 2020 Industry Key Players, Trends, Sales, Supply, Demand, Analysis & Forecast By 2027

 Fibromyalgia syndrome co-exists with other painful conditions, such as migraine and other types of headaches, temporomandibular joint disorders, irritable bowel syndrome (IBS), and interstitial cystitis. The treatment of fibromyalgia includes both targeted and symptomatic approach. Till date, there are only three FDA approved drugs for the fibromyalgia treatment, i.e., Lyrica (PFIZER), Cymbalta (Eli Lilly and Company), and Savella (Allergan plc). However, there are few other drugs prescribed by physicians to control the symptoms of fibromyalgia such as pain relievers, muscle relaxants, and traditional Chinese medicine.

Growing geriatric population, increasing cases of rheumatic diseases, growing awareness among the population, and rising incidences of traumatic stress and road accidents are the key factors driving the Chinese fibromyalgia market. According to a study published in the Arthritis Care & Research journal in 2017, fibromyalgia and related symptoms worsen the functional status of individuals with rheumatoid arthritis. Around 15%-30% of patients with rheumatic disorders have co-morbid fibromyalgia syndrome.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5630 

However, difficulty in diagnosis of the disease, and stringent FDA regulations may hinder the growth of the market to an extent. As fibromyalgia syndrome is associated with other chronic diseases so, its diagnosis takes a long time. As fibromyalgia syndrome is associated with other chronic diseases so, its diagnosis takes a long time. According to a study published in Arthritis Research & Therapy journal in 2017, in Taiwan, the risk of coronary heart disease in fibromyalgia patients was 47% higher than the general population.

The Chinese fibromyalgia market is expected to grow at a CAGR of 18.7% during the forecast period.

Key Players

Some of key the players in the market are Pfizer, GlaxoSmithKline, AstraZeneca, Roche, Astellas Pharma, Eli Lilly and Company, Johnson & Johnson Services, Inc., SANOFI, Bayer AG, AbbVie, ALLERGAN, Boehringer Ingelheim, Cephalon, Inc., Vertical Pharmaceuticals, Sunovion Pharms Inc, Jazz Pharmaceuticals, ABBOTT, NOVARTIS, and others.

Regional Analysis

South Central China accounted for the major share of the market owing to the rising prevalence of fibromyalgia in this region. Rising cases of chronic rheumatic diseases are also capable of fuelling the fibromyalgia market in China. Prevalence of rheumatoid arthritis is around 0.35%, with the significantly higher rate in Northern China as compared to the Southern part.

The rising healthcare expenditure is also propelling the growth of the market. In China, the total expenditure on health per capita in 2014 was USD 731, as per the World Health Organization (WHO) in 2015. The health expenditure in China grew at a rate of 11.6% per year, suggested by a study published in BMC Health Services Research journal in 2017. This rate is much faster than the growth of the country’s economy, i.e., 9.9% per year.

Segmentation

The Chinese fibromyalgia market is segmented on the basis of diagnosis, treatment, and end-user.

On the basis of the diagnosis, the market is classified into laboratory evaluation and presence of central sensitization.

On the basis of the treatment, the market is segmented into targeted treatment and symptomatic treatment.

On the basis of the end-users, the market is segmented into hospitals, clinics, diagnostic centers, and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/chinese-fibromyalgia-market-5630